While Recursion Pharmaceuticals Inc has underperformed by -4.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RXRX fell by -42.66%, with highs and lows ranging from $12.36 to $3.79, whereas the simple moving average fell by -23.28% in the last 200 days.
On May 22, 2023, Morgan Stanley started tracking Recursion Pharmaceuticals Inc (NASDAQ: RXRX) recommending Equal-Weight. A report published by Needham on March 16, 2023, Initiated its previous ‘Buy’ rating for RXRX. KeyBanc Capital Markets also rated RXRX shares as ‘Overweight’, setting a target price of $20 on the company’s shares in an initiating report dated September 16, 2022. SVB Leerink March 04, 2022d its ‘Outperform’ rating to ‘Mkt Perform’ for RXRX, as published in its report on March 04, 2022. Berenberg’s report from September 21, 2021 suggests a price prediction of $37 for RXRX shares, giving the stock a ‘Buy’ rating. SVB Leerink also rated the stock as ‘Outperform’.
Analysis of Recursion Pharmaceuticals Inc (RXRX)
Further, the quarter-over-quarter increase in sales is 6.89%, showing a positive trend in the upcoming months.
One of the most important indicators of Recursion Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -86.10% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.11, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and RXRX is recording 22.66M average volume. On a monthly basis, the volatility of the stock is set at 6.63%, whereas on a weekly basis, it is put at 3.02%, with a loss of -10.38% over the past seven days. Furthermore, long-term investors anticipate a median target price of $7.17, showing growth from the present price of $4.92, which can serve as yet another indication of whether RXRX is worth investing in or should be passed over.
How Do You Analyze Recursion Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 23.55%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 60.52% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RXRX shares are owned by institutional investors to the tune of 60.52% at present.
